PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib. Shots: If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months. Lilly is evaluating Baricitinib for SLE, for which…

BySenior EditorOctober 12, 2020

TOP 20

Top 20 Oncology Companies by Total Products of 2019

To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…

ByPrince GiriSeptember 24, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2020

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…

BySenior EditorJuly 24, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2020

The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…

BySenior EditorJuly 7, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2020

The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020…

BySenior EditorJune 19, 2020

TOP 20

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…

ByPrince GiriApril 24, 2020

TOP 20

Top COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at an unprecedented speed to develop vaccines- treatments- and tests This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. This first part is…

ByPrince GiriApril 17, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named 'SARS-CoV-2'(severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named 'Coronavirus Disease 2019'(COVID-19). The outbreak of the respiratory disease was first detected in Wuhan…

BySenior EditorFebruary 28, 2020

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

Top 20 Oncology Companies by Total Products of 2019

Insights+: The US FDA New Drug Approvals in June 2020

PharmaShots’ Key Highlights of Second Quarter 2020

Insights+ Key Biosimilars Events of June 2020

Insights+: The US FDA New Drug Approvals in May 2020

Top 20 BioPharma Companies based on 2019 Total Revenue

Top COVID-19 Deals (Part I): Biopharma Drug Development

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Contact US

FOLLOW US